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Neuropad is currently a categorical visual screening test that identifies diabetic patients at risk of foot ulceration. The diagnostic
performance of Neuropad was compared between the categorical and continuous (image-analysis (Sudometrics)) outputs to
diagnose diabetic peripheral neuropathy (DPN). 110 subjects with type 1 and 2 diabetes underwent assessment with Neuropad,
Neuropathy Disability Score (NDS), peroneal motor nerve conduction velocity (PMNCV), sural nerve action potential (SNAP),
Deep Breathing-Heart Rate Variability (DB-HRV), intraepidermal nerve fibre density (IENFD), and corneal confocal microscopy
(CCM). 46/110 patients had DPN according to the Toronto consensus. The continuous output displayed high sensitivity and
specificity for DB-HRV (91%, 83%), CNFD (88%, 78%), and SNAP (88%, 83%), whereas the categorical output showed high
sensitivity but low specificity. The optimal cut-off points were 90% for the detection of autonomic dysfunction (DB-HRV) and
80% for small fibre neuropathy (CNFD).The diagnostic efficacy of the continuous Neuropad output for abnormal DB-HRV (AUC:
91%, 𝑃 = 0.0003) and CNFD (AUC: 82%, 𝑃 = 0.01) was better than for PMNCV (AUC: 60%). The categorical output showed no
significant difference in diagnostic efficacy for these same measures. An image analysis algorithm generating a continuous output
(Sudometrics) improved the diagnostic ability of Neuropad, particularly in detecting autonomic and small fibre neuropathy.
1. Introduction
Diabetic peripheral neuropathy (DPN) is a progressivemani-
festation of diabetes with length-dependent and symmetrical
damage of nerve fibers [1]. It is of critical importance to detect
early neuropathy in the distal small nerve fibres in order to
predict and prevent progressive morbidity that may involve
pain, imbalance, foot deformities, ulceration, and amputation
[2, 3]. However, early subclinical neuropathy cannot be
diagnosed with currently endorsed clinical tests such as the
10 gmonofilament or NeuropathyDisability Score (NDS) [4].
These methods primarily identify patients with established
DPN who are already at high risk of foot ulceration. Given
that small fibre neuropathy (SFN) is the earliestmanifestation
of DPN and plays a crucial role in the aetiopathogenesis of
foot ulceration due to loss of pain sensation, anhidrosis, and
deranged tissue blood flow, a screening test should ideally
evaluate these fibres.
Several tests for evaluating SFN have been established
in clinical practice and research settings but each has their
own limitations. Warm perception threshold (WPT) testing
detects nerve dysfunction but is expensive (m20K) and limited
by the need for subjective responses and variable repro-
ducibility. Deep Breathing-Heart Rate Variability (DB-HRV)
detects autonomic nerve dysfunction but again requires
expensive equipment (m10K) and patient cooperation with
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potential confounders such as medication and caffeine con-
sumption [2]. Intraepidermal nerve fibre density (IENFD) is
the gold standard for assessing small nerve fibre morphology
from skin biopsies but is invasive and painful [5]. Corneal
confocal microscopy (CCM) represents an alternative imag-
ing technique which is a noninvasive alternative to skin
biopsy [6]. It has been validated for assessing early small fibre
damage and repair but requires expensive equipment and
trained staff to perform the test. Sudomotor abnormalities
can be detected using skin biopsy or measures of sweating
using the QSART [7] or Sudoscan devices [8]. Neuropad
measures sweat production based on a colour change in a
cobalt II compound from blue to pink to produce a categor-
ical output but has a moderate diagnostic performance for
DPN [9–13]. Neuropad specificity for large fibre neuropathy
is low (50–64%), whereas for small fibre neuropathy SFN it is
much higher (80%) [14]. Other studies have also reported low
specificity (45–67.2%) for large fibre neuropathy measures
such as NDS and Vibration PerceptionThreshold [12, 15–17].
The diagnostic validity of the Neuropad response has
been tested primarily for categorical [10, 11, 15–17] rather than
a continuous output [14]. Hence for the categorical output
there are only three possible outcomes: normal, intermediate,
or abnormal. Whilst this provides an output, which is simple
to interpret by both the patient and clinician, it lacks discrim-
ination forminor worsening or improvement. To address this
we have previously proposed a continuous output expressed
as a percentage colour change determined visually [14], but
this is subjective with a coefficient of repeatability for intra-
and interobserver variability of 0.3 and 0.4, respectively.
This argues for the development of image analysis software
to rapidly and consistently grade the colour change to a
percentage output, enabling a continuous quantitative and
completely reproducible measure of sudomotor small fibre
dysfunction.
In the present study we have tested the diagnostic ability
of Sudometrics software, which can quantify the Neuropad
response in a range from 0 to 100% against the established
categorical output for measures of SFN and LFN.
2. Research Design and Methods
The participants in the study were recruited from the Man-
chester Diabetes Centre, Manchester Royal Infirmary in
Manchester, UK. The study was performed at the Wellcome
Trust Clinical Research Facility/NIHR from September 3,
2012, to May 30, 2014, involving 110 subjects with diabetes
mellitus (DM) (84 type 1 DM and 26 type 2 DM) with an
average age of 53± 13 years. We estimated that the minimum
sample required to detect significant difference in Neuropad
response between the group with DPN and without DPNwas
68 participants by means of an unpaired 𝑡-test and with a
power of 95%. Exclusion criteria included history of neuropa-
thy due to nondiabetic cause and corneal trauma or surgery.
This study was approved by the Local Research Ethics com-
mittee and all patients gave informed consent to take part in
the study. The research adhered to the tenets of the Decla-
ration of Helsinki.
2.1. Demographic Measures. All study participants under-
went assessment of their glycated haemoglobin (HbA1c),
bodymass index (BMI), systolic and diastolic blood pressure,
cholesterol, and triglycerides.
2.2. Functional Tests of Small Nerve Fibres. The function of
the small cholinergic and adrenergic nerves that regulate
sweating in the feet was measured by Neuropad (miro Ver-
bandstoffe, Wiehl-Drabenderho¨he, Germany) [18]. The plas-
ter was applied to the plantar aspect of the 1st metatarsal
head after callus removal and removed after 10 minutes.
Immediately after removal, the plaster was scanned in high
resolution 600 dpi by the Fujitsu FI-60F fast flatbed passport
scanner (Response Technical Services Ltd, Surrey, UK). The
percentage colour change in pink over the whole area of
Neuropad was estimated by Sudometrics. The algorithm is
based on the intensity-level analysis of the pink colour. Once
the area of Neuropad is segmented using a variable threshold
a colour histogram is computed and the pink percentage is
extracted as a metric. A morphological set operation is con-
ducted to remove background noise and better define the
pad area. Sudometrics is available to all potential collabora-
tors solely for research purposes (non-for-profit/noncom-
mercial). It is protected by the University of Manchester in
the form of license agreement which can be requested online
(http://www.click2go.umip.com/i/software/Biomedical Soft-
ware/Sudometrics.html).
Cardiac autonomic function was measured using the
ANX 3.0 autonomic nervous system monitoring device
(ANSAR Medical Technologies Inc., Philadelphia, US)
[19]. Deep Breathing-Heart Rate Variability (DB-HRV) was
assessed by R-R interval variation via surface electrodes. DB-
HRVwas recorded over 1min at a frequency of 6 breaths/min.
Thermal discrimination threshold testing was under-
taken on the dorsum of the left foot using the MEDOC TSA
II (Medoc Ltd., Ramat Yishai 30095, Israel) and method of
limits [20].
2.3. Structural Tests of Small Nerve Fibres
2.3.1. Corneal Confocal Microscopy. Patients underwent
examination with the Heidelberg Retina Tomograph (HRT
III RCM) in vivo corneal confocal microscope (IVCCM)
(Heidelberg Engineering GmbH, Heidelberg, Germany)
using our established methodology [21]. The section mode
enables manual acquisition and storage of single images of
the central cornea with a lateral resolution of approximately
2 𝜇m/pixel and final image size of 400 × 400 pixels of the
subbasal nerve plexus. Corneal Nerve Fibre Density (CNFD),
the total number of nerve fibres (no./mm2), Corneal Nerve
Branch Density (CNBD), the total number of nerve branches
(no./mm2), and Corneal Nerve Fibre Length (CNFL), the
total length of all nerve fibres and branches (mm/mm2)
within the area of cornea captured by the image were
quantified from ∼5 adjacent images/subject, using purpose
built manual image analysis software called CCMetrics [21].
CCMetrics is available to all potential collaborators solely
for research purposes (non-for-profit/noncommercial). It is
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protected by the University of Manchester in the form of
license agreement which can be requested online (http://
www.human-development.manchester.ac.uk/ena/ACCMet-
ricsuserinstructions#Researchlicenceagreement).
2.3.2. Intraepidermal Nerve Fibre Density. A 3mm punch
skin biopsy was taken from the dorsum of the foot under 1%
lidocaine local anaesthesia. Skin samples were immediately
fixed in 4% (wt/vol.) paraformaldehyde for 24 h and then
cryoprotected in sucrose for 18 h and cut into 50𝜇m thick
sections. Immunohistochemistry was performed as previ-
ously described [9]. An image analysis camera AxioCam
MRc (Ziess, Germany) and Leica QWin StandardV2.4 (Leica
Microsystem Imaging, Cambridge, UK) were used to quan-
tify intraepidermal nerve fibre density (IENFD), which is the
total number of nerve fibres per millimeter length of epider-
mis (no./mm).
2.4. Neuropathy Assessments. All patients underwent an
assessment of neuropathy based on a standard protocol
including Neuropathy Disability Score (NDS) to classify
participants into without (NDS 0–2) and with (NDS 3–10)
neuropathy [4, 22]. Quantitative sensory testing included an
assessment of Vibration Perception Threshold (VPT), mea-
sured using a Neurothesiometer (Horwell, Scientific Labora-
tory Supplies, Wilford, Nottingham, UK) and warm percep-
tion thresholds (WPT) using the method of limits with the
MEDOC TSA II (Medoc Ltd., Ramat Yishai 30095, Israel)
on the dorsum of the left foot. Electrodiagnostic studies
were undertaken using a Dantec “Keypoint” system (Dantec
Dynamics Ltd., Bristol, UK) equipped with a DISA temper-
ature regulator to keep limb temperature constantly between
32 and 35∘C. Sural nerve conduction velocity (SNCV), sural
sensory nerve action potential (SNAP), peronealmotor nerve
conduction velocity (PMNCV), and peroneal motor nerve
action potential (PMNAP) were assessed in the right lower
limb by a consultant neurophysiologist.
2.5. Study Definition of Diabetic Peripheral Neuropathy. The
Toronto Diabetic Neuropathy Expert group recommenda-
tion was followed to define DPN: (a) abnormal PMNCV
(<42m/s) and (b) abnormal symptoms or signs of neuropa-
thy, NDS (>2) [23].
To define an abnormal result for each of the measures of
neuropathy we have used a mean ± 2 SD cut-off based on our
control population (𝑛 = 104).
2.6. Statistical Analysis. Statistical analysis was performed
using StatsDirect statistical software, version 2.7.9. We exam-
ined the distribution of the data by means of relevant
histograms and the Shapiro-Wilk test. All data were expressed
asmedian (5th percentile, 95th percentile). Mann-Whitney𝑈
test was performed to analyse differences between the medi-
ans. A 𝑃 value <0.05 was considered statistically significant.
Receiver operating characteristic (ROC) curve analysis
was used to compare the diagnostic accuracy of Neuropad
against measures of large and small nerve fibre damage. ROC
curve analysis established the area under the curve (AUC) to
Table 1: Comparison of clinical data of study participants with type
1 and 2 diabetes according to the presence or absence of neuropathy
defined by the Toronto criteria. Data are medians (5th percentile,









Age 45 (21, 71) 62 (44, 75) <0.0001
Diabetes duration (years) 19 (3, 48) 40 (8, 58) <0.0001
Gender (male/female) 39/25 33/13
Type of diabetes (I/II) 52/12 32/14
HbA1c % [mmol/mol] 7.6 (6.9, 8.4)[60 (51, 68)]
8.6 (8, 9.2)
[69 (59, 77)] 0.006
BMI (kg/m2) 26.0 (21, 38) 29.0 (21, 38) 0.09
Systolic BP (mmHg) 123 (99, 154) 140 (108, 169) 0.004
Diastolic BP (mmHg) 67 (56, 78) 67 (56, 83) 0.9
Cholesterol (mmol/L) 4.2 (2.9, 6.9) 3.8 (2.7, 6) 0.17
Triglyceride (mmol/L) 1 (0.5, 2) 1.1 (0.4, 2.9) 0.4
Large fibre assessments
NDS 0.5 (0, 5) 5.5 (3, 10) <0.0001
VPT (V) 6.3 (3, 19) 21.8 (8, 41) <0.0001
SNAP (𝜇V) 13 (4.6, 28) 4.9 (0.4, 19) <0.0001
SNCV (m/s) 43.8 (40, 51.9) 39.5 (27, 45.7) <0.0001
PMNAP (𝜇V) 4.6 (1, 7.6) 1.8 (0.1, 5) <0.0001
PMNCV (m/s) 44.1(39.1, 49.1) 39.3 (19, 45) <0.0001
Small fibre assessments
IENFD (no./mm) 6.8 (0.5, 13.5) 3.5 (0.3, 15.3) <0.0001
CNFD (no./mm2) 30.0(15.6, 43.8)
21.4
(6.3, 36.5) 0.005
CNBD (no./mm2) 90.1(21.9, 214)
62.5
(3.1, 220.3) 0.1
CNFL (mm/mm2) 25.0(12.8, 33.5)
19.6
(4.6, 34.0) 0.03
DB-HRV (beats per min) 25 (6, 45) 10 (4, 39) 0.002
WPT (∘C) 38.5(34.7, 46.7)
42.0
(36.3, 49.8) <0.0001
Neuropad (%) 61.5 (0, 99) 18.0 (0, 99) 0.01
determine the optimal sensitivity and specificity of the Neu-
ropad test. Statistical difference between two ROC curves was
expressed in 𝑃 value as described by Hanley andMcNeil [24].
3. Results and Discussion
3.1. Clinical Data. Of the 110 subjects with diabetes, 46 were
diagnosed with and 64 without diabetic peripheral neu-
ropathy (DPN).The demographic and clinical characteristics
of the participants with and without DPN are presented
in Table 1. BMI, diastolic blood pressure, cholesterol, and
triglyceride levels did not differ between the two groups, but
HbA1c (𝑃 = 0.006), age (𝑃 < 0.0001), duration of diabetes
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Table 2: Comparing the diagnostic performance of Neuropad between the continuous and the categorical output. The evaluation was
performed against large (Neuropathy Disability Score (NDS) and Vibration PerceptionThreshold (VPT), sural sensory nerve action potential
(SNAP), sural nerve conduction velocity (SNCV), peroneal motor nerve action potential (PMNAP), and peroneal motor nerve conduction
velocity (PMNCV)) and small (intraepidermal nerve fibre density (IENFD), Corneal Nerve Fibre Density (CNFD), Corneal Nerve Branch
Density (CNBD), Corneal Nerve Fibre Length (CNFL), Deep Breathing-Heart Rate Variability (DB-HRV), and warm perception thresholds
(WPT)) nerve fibre assessments as reference methods using ROC curve analysis.
Variables
Continuous output Categorical output











NDS (>2) 67 71, 58 66 69, 62 0.46
VPT (>14V) 75 80, 71 66 70, 57 0.33
SNAP (<3𝜇V) 86 85, 83 82 100, 55 0.35
SNCV (<43m/s) 62 66, 61 61 61, 59 0.46
PMNAP (<2𝜇V) 63 67, 54 61 62, 50 0.44
PMNCV (<42m/s) 60 62, 58 57 60, 53 0.39
Small fibre assessments
IENFD (<4 no./mm) 63 65, 54 55 56, 51 0.27
CNFD (<24 no./mm2) 82 88, 78 79 89, 63 0.37
CNBD (<18 no./mm2) 79 83, 72 71 100, 47 0.32
CNFL (<14mm/mm2) 80 89, 75 71 90, 50 0.26
DB-HRV (<10 beats per min) 91 91, 83 78 82, 59 0.06
WPT (>42∘C) 69 75, 60 66 69, 53 0.38
(𝑃 < 0.0001), and systolic blood pressure (𝑃 = 0.004) were
significantly higher in those with DPN.The group with DPN
had a significantly higher NeuropathyDisability Score (NDS)
and Vibration Perception Threshold (VPT) and significantly
lower sural sensory nerve action potential (SNAP), sural
nerve conduction velocity (SNCV), peroneal motor nerve
conduction velocity (PMNCV), and peroneal motor nerve
action potential (PMNAP) (𝑃 < 0.0001 for all comparisons).
NDS and nerve conduction parameters had substantial vari-
ability indicating that the groupwithDPNhad awide severity
of neuropathy. Similarly the DPN group had a significantly
lower Neuropad response (𝑃 = 0.01), intraepidermal nerve
fibre density (IENFD) (𝑃 < 0.0001), CNFD (𝑃 = 0.005),
CNFL (𝑃 = 0.03), and Deep Breathing-Heart Rate Variability
(DB-HRV) (𝑃 = 0.002) with a significantly higher warm
perception threshold (WPT) (𝑃 < 0.0001).
3.2. Neuropad Diagnostic Performance for Diabetic Peripheral
Neuropathy. The continuous output was generated using
image analysis software (Sudometrics) to enable rapid and
consistent quantification of the Neuropad response.The eval-
uation of colour change in percentage was completely repro-
ducible with a coefficient of repeatability of 1. The diagnostic
performance between the continuous and the categorical
output is presented in Table 2. The continuous output dis-
played high sensitivity and specificity for DB-HRV (91%,
83%), CNFD (88%, 78%), and SNAP (88%, 83%) and high
sensitivity with moderate specificity for CNBD (83%, 72%),
CNFL (89%, 75%), and VPT (80%, 71%), respectively. For
the categorical output the sensitivity was equally high but
the specificity was lower for DB-HRV (82%, 59%), CNFD
(89%, 63%), CNBD (100%, 47%), CNFL (90%, 50%), SNAP
(100%, 55%), and VPT (70%, 57%), respectively. This echoes
our recent findings [14] that a continuous Neuropad output
has high sensitivity (83%) and specificity (80%) for detecting
structural small fibre damage.
3.3. Small versus Large Fibre Neuropathy. Early subclinical
SFN precedes large fibre impairment with numbness and
foot ulceration [1]. Currently, advocated clinical tests such as
the 10 g monofilament or Neuropathy Disability Score (NDS)
cannot detect patients with early neuropathy [4]. Neuropad
has been promoted as an inexpensive, practical, first-line
diagnostic screening test for subclinical SFN [9–11].
This study highlights the parameters for which the
Neuropad is most useful for the diagnosis of early DPN.
Furthermore, it clearly shows that a continuous output for
Neuropad significantly improves its diagnostic ability to
detect autonomic and SFN than measures of large fibre neu-
ropathy.The AUC for DB-HRV (91%) was significantly larger
than for NDS (67%, 𝑃 = 0.001), VPT (75%, 𝑃 = 0.02), SNCV
(62%, 𝑃 = 0.0009), PMNAP (63%, 𝑃 = 0.003), and PMNCV
(60%, 𝑃 = 0.0003). Similarly, the AUC for CNFD (82%) was
significantly larger than for NDS (67%, 𝑃 = 0.05), SNCV
(62%, 𝑃 = 0.02), PMNAP (63%, 𝑃 = 0.04), and PMNCV
(60%, 𝑃 = 0.01). The AUC for CNFL (80%) was significantly
larger than for PMNCV (60%, 𝑃 = 0.05). Unlike the con-
tinuous output, the categorical output showed no significant
difference between small and large fibre damage. Indeed, we
have previously shown that Neuropad correlates better with



























































































Figure 1: ROC curve analysis was used to compare the diagnostic accuracy of Neuropad in detecting large with small nerve fibre damage
(black line). The grey line is the null value of the ROC curve. The AUC for large nerve fibre damage was (a) 75% for Vibration Perception
Threshold (VPT) (SE: 0.049, 95% CI 0.53–0.97) and (b) 86% for sural sensory nerve action potential (SNAP) (SE: 0.04, 95% CI 0.42–1).
The AUC for small nerve fibre damage was (c) 82% for Corneal Nerve Fibre Density (CNFD) (SE: 0.053, 95% CI 0.48–1), (d) 91% for Deep
Breathing-Heart Rate Variability (DB-HRV) (SE: 0.031, 95% CI 0.49–1), (e) 63% for intraepidermal nerve fibre density (IENFD) (SE: 0.068,
95% CI 0.45–0.81), and (f) 69% for warm perception thresholds (WPT) (SE: 0.05, 95% CI 0.49–0.88).
heart rate variability than NDS [9]. Of relevance, previously,
CNBD, CNFD, and CNFL have also been shown to correlate
highly significantly with heart rate variability [25].
Since Neuropad is a diagnostic screening test for sudo-
motor function and hence, for SFN, we propose that the
optimal cut-off point for small fibre dysfunction is 90% and
for small fibre structural damage it is 80%, based onDB-HRV
and corneal nerve morphology (CNBD, CNFD, and CNFL),
respectively. The optimal cut-off point is the percentage
of Neuropad colour change to pink defining normal from
abnormal. Our current data are consistent with previous
studies showing a strong association between Neuropad and
autonomic neuropathy [19] as well as small fibre neuropathy
assessed using corneal confocal microscopy [26]. However,
interestingly there is considerable variability for the diagnos-
tic ability (AUC) of a continuous Neuropad output amongst
the different measures of small and large fibre neuropathy.
Thuswhilst there is a good diagnostic ability for SNAP (86%),
it was only moderate for SNCV (62%), PMNCV (60%),
and PMNAP (63%) as well as VPT (75%). Figure 1 shows
that Neuropad exhibited a higher AUC for DB-HRV (91%),
rather thanWPT (69%), supporting the expected association
with autonomic rather than somatic small fibre dysfunction.
Rather surprisingly the diagnostic performance of Neuropad
to identify structural pathology of the small fibres was better
for CNFD (82%), CNBD (79%), and CNFL (80%) than
IENFD (63%). These different associations were similar but
not as strong with the categorical output (Table 2).
This study has several strengths and limitations. We
utilised a detailed and comprehensive evaluation of a wide
range of gold standard techniques to quantify diabetic neu-
ropathy, which enabled us to dissect and define the diagnostic
ability of the Neuropad in a large cohort of individuals with
type 1 and 2 diabetes. Furthermore, unlike all previous studies
[9, 12, 13], including our recent study [14] the estimation
of colour change for the Neuropad has been categorical or
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subjective and hencemore liable to error. In the current study
we have utilized an image analysis algorithm (Sudometrics),
to provide a continuous and completely reproducible output.
DPN was of course diagnosed using the Toronto consensus,
which is large fibre weighted and incorporation of a small
fibre abnormality as per a previous consensus may well
have further improved the diagnostic ability of Neuropad as
observed with the much higher AUCs with measures of
small fibre neuropathy [3]. We were not able to account for
the potential confounding effect of age, diabetes duration,
HbA1c, systolic blood pressure, and BMI on the relationship
that Neuropad has with small and large fibre damage because
of their inherent influence on DPN. We believe our data
support the use of a continuous output for Neuropad as a
diagnostic test for DPN, but a longitudinal study is required
to assess the predictive and hence prognostic ability of this
simply administered test. Furthermore, it is important to
note that the Sudometrics output requires a high resolution
scanner and image analysis software, which may be deemed
cumbersome and takes from the simple visual output pro-
vided by Neuropad to the patient and clinician. However, we
would propose that given the advances in technology this
whole process could easily be incorporated into amobile App,
which the manufacturer of Neuropad should explore.
4. Conclusions
In conclusion, the current study shows that the diagnostic
efficacy of Neuropad can be considerably enhanced using
Sudometrics, an automated continuous output as opposed to
the categorical output, particularly for evaluating SFN. Given
the advances in mobile technology, this merits exploration to
develop a user friendly App for this purpose.
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